Clinical Trial Update: Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Ibrutinib, Rituximab, Venetoclax, and combination chemotherapy in newly diagnosed mantle cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• IMBRUVICA (IBRUTINIB)
• Rituxan (rituximab)
• Venclexta (venetoclax)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Mantle Cell Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING